Affordable Access

deepdyve-link
Publisher Website

Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy

Authors
  • Fischer-Valuck, Benjamin W.1
  • Michalski, Jeff M.2
  • Harton, Joanna G.3
  • Birtle, Alison4, 5
  • Christodouleas, John P.6
  • Efstathiou, Jason A.7
  • Arora, Vivek K.8
  • Kim, Eric H.9
  • Knoche, Eric M.8
  • Pachynski, Russell K.8
  • Picus, Joel8
  • Rao, Yuan James10
  • Reimers, Melissa8
  • Roth, Bruce J.8
  • Sargos, Paul11, 12
  • Smith, Zachary L.9
  • Zaghloul, Mohamed S.13, 14
  • Gay, Hiram A.2
  • Patel, Sagar A.1
  • Baumann, Brian C.2, 6
  • 1 Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
  • 2 Department of Radiation Oncology, Washington University School of Medicine in St Louis, St Louis, MO
  • 3 Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
  • 4 Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK
  • 5 University of Manchester, Manchester, UK
  • 6 Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
  • 7 Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
  • 8 Division of Oncology, Washington University School of Medicine in St Louis, St Louis, MO
  • 9 Division of Urology, Washington University School of Medicine in St Louis, St Louis, MO
  • 10 Department of Radiation Oncology, George Washington University, Washington D.C.
  • 11 Department of Radiation Oncology, Jewish General Hospital, Montreal, QC, Canada
  • 12 Department of Radiotherapy, Institut Bergonié, Bordeaux, France
  • 13 Radiation Oncology Department, Children’s Cancer Hospital, Cairo, Egypt
  • 14 Radiation Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt
Type
Published Article
Journal
Clinical Genitourinary Cancer
Publisher
Elsevier
Publication Date
Jun 22, 2020
Volume
19
Issue
1
Pages
41–46
Identifiers
DOI: 10.1016/j.clgc.2020.06.005
PMID: 33187904
PMCID: PMC7306737
Source
PubMed Central
Keywords
Disciplines
  • Original Study
License
Unknown

Abstract

Limited data are available on the effect of treatment delays for initiating chemoradiotherapy (CRT) for muscle-invasive bladder cancer. We used the National Cancer Database and found that 1387 patients had started CRT < 90 days after transurethral resection of bladder tumor (TURBT) compared with 197 with delayed CRT (≥ 90 days after TURBT). On multivariable analysis, delayed CRT was not associated with differences in overall survival. These results suggest that short, strategic treatment delays during a pandemic can be considered based on clinician judgment.

Report this publication

Statistics

Seen <100 times